PUBLIC COMPANY
saveHELUS Pharma
updated 3mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Helus Pharma notches successful Phase 3 depression readoutHelus Pharma, part of the budding class of psychedelics companies, said its lead drug improved depression symptoms compared to placebo, but investors appeared slightly skittish about the safety pro…endpoints · 1d ago
- Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depressionHelus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious a…biospace · 1d ago
- STAT+: Helus’ psychedelic drug improved depression in study but faces safety questionsA psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.stat · 1d ago
- Helus' chemically modified psychedelic hits key goals in phase 3 depression trialHelus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.fiercebiotech · 1d ago
- Chutes & Ladders—BioNTech brings in Sobi CEOAfter a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…fiercebiotech · 3mo ago
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 3mo ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 4mo ago
- Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months→ Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the new…endpoints · 6mo ago
comments(0)
5-min edit window · permanent after that